drugset
drugset / Trial / NCT04329728

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

NCT04329728 ↗

Phase 1/2 Recruiting 144 enrolled AVM Biotechnology Inc Medpace, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

Timeline

Start
2020-11-06
Primary completion
2027-11-30
Completion
2028-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AVM0703 Small molecule 18 mg/kg Intravenous
Subject AVM0703 Small molecule 21 mg/kg Intravenous

Indications

lymphoma